Journal article
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
- Abstract:
-
BACKGROUND: Traditionally, vaccine development against the blood-stage of Plasmodium falciparum infection has focused on recombinant protein-adjuvant formulations in order to induce high-titer growth-inhibitory antibody responses. However, to date no such vaccine encoding a blood-stage antigen(s) alone has induced significant protective efficacy against erythrocytic-stage infection in a pre-specified primary endpoint of a Phase IIa/b clinical trial designed to assess vaccine efficacy. Cell-me...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 657.5KB, Terms of use)
-
- Publisher copy:
- 10.1371/journal.pone.0031208
Authors
Funding
+ Wellcome Trust
More from this funder
Grant:
084113/Z/07/Z
RTEI0
45488/Z/05
Funding agency for:
Duncan, C
Hill, A
Bibliographic Details
- Publisher:
- Public Library of Science
- Journal:
- PloS One More from this journal
- Volume:
- 7
- Issue:
- 2
- Article number:
- e31208
- Publication date:
- 2012-01-01
- DOI:
- EISSN:
-
1932-6203
- ISSN:
-
1932-6203
Item Description
- Language:
-
English
- Keywords:
-
- Pubs id:
-
pubs:312882
- UUID:
-
uuid:d9c03039-aa17-4fab-95d8-ddc5c792d23d
- Local pid:
-
pubs:312882
- Source identifiers:
-
312882
- Deposit date:
-
2012-12-19
Terms of use
- Copyright holder:
- Sheehy et al
- Copyright date:
- 2012
- Notes:
- Copyright © 2012 Sheehy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record